February 2026
The cancer biomarkers market size stood at US$ 38.62 billion in 2025, grew to US$ 43.54 billion in 2026, and is forecast to reach US$ 128 billion by 2035, expanding at a CAGR of 12.73% from 2026 to 2035.
Because they offer important insights into illness diagnosis, prognosis, response to therapy, and tailored medicine, biomarkers are essential in the healthcare industry. In particular, developments in molecular biology technologies created for the detection of tumor biomarkers have greatly advanced personalized medicine and improved the outcomes for cancer patients. Over the past few decades, there has been a steady advancement in the exploration and discovery of novel, sensitive, specific, and accurate tumor biomarkers.
The cost of developing biomarkers for cancer is rising steadily. Companies in the pharmaceutical and research industries are looking for new biomarkers to increase their ability to diagnose and treat patients. Research on cancer biomarkers received USD 2.8 billion in fiscal year 2023, a 15% increase, according to the National Institutes of Health (NIH).
Funding recessions may have an impact on investments in cancer biomarker research, causing R&D (Research and Development) operations to be delayed or scaled back. Both businesses and research institutions may be impacted, leading to budget cuts that restrict funding for creating novel cancer biomarkers or enhancing current tests.
| Key Elements | Scope |
| Market Size in 2026 | USD 43.54 Billion |
| Projected Market Size in 2035 | USD 128 Billion |
| CAGR (2026 - 2035) | 12.73% |
| Leading Region | North America |
| Market Segmentation | By Type, By Biomolecule, By Application, By Technology, By Region |
| Top Key Players | Abbott, Sino Biological Inc, Hologic, Inc, Agilent Technologies, Merck & Co. Inc, F. Hoffmann-La Roche AG, Illumina, Inc., Affymetrix Inc, Thermo Fisher Scientific Inc, QIAGEN |
Which Type Segment Dominated the Cancer Biomarkers Market?
By type, the breast cancer segment held the major share of the market by 35%. In 2020, there were more than 2.3 million new instances of breast cancer and 685,000 fatalities. It is estimated that the number of new cases and annual deaths from breast cancer will reach over 3 million by 2040 due to population growth and aging alone.
How the Genetic Biomarkers Segment Dominated the Cancer Biomarkers Market?
By biomolecule, the genetic biomarkers segment dominated the market by 40%. Genetic biomarkers are used as a therapeutic guide to help patients choose the best course of treatment. Targeted medicines, which directly target the molecular processes implicated in cancer, are beneficial for patients with certain genetic alterations.
By biomolecule, the epigenetics segment is estimated to grow at the fastest rate during the forecast period. One of the characteristics of cancer is a global shift in the epigenetic landscape. The potential subject of epigenetic therapy has emerged as a result of the reversible nature of epigenetic aberrations. The FDA has approved three epigenetic medications for the treatment of cancer, indicating that this discipline is already making progress.
| Segment | Share 2025 (%) |
| Diagnostics | 40% |
| Drug Discovery and Development | 25% |
| Personalized Medicine | 25% |
| Others | 10% |
Why Did the Diagnostics Segment Dominate the Cancer Biomarkers Market?
By application, the diagnostics segment accounted for dominating the market by 40%. Since they may be used to detect and comprehend the risk of developing cancer and the underlying causes, diagnose a tumor early, track the course of the illness, and assess the efficacy of treatment resistance, biomarkers are essential. It is anticipated that biomarkers will become increasingly more important in the future for the diagnosis, treatment, and prevention of cancer.
By application, the personalized medicine segment is estimated to grow at the fastest rate during the forecast period. Because biomarkers allow oncologists to customize therapies based on the distinct molecular profile of each patient's tumor, personalized medicine marks a paradigm shift and a turning point in the management of cancer.
What Made Imaging Technologies the Dominant Segment in the Cancer Biomarkers Market?
By technology, the imaging technologies segment held the major share of the market by 60%. In oncology, imaging biomarkers (IBs) and biospecimen-derived biomarkers are widely used. The healthcare industry often uses a large number of IBs. IBs offer easily accessible, affordable, non-invasive methods for screening, tumor detection, and patient serial monitoring, which includes evaluating treatment response and spotting side effects. IBs may be used to map the geographic variability inside tumors, follow a specific tumor over time, and independently assess many lesions within a single person.
By technology, the OMICS segment is estimated to grow at the fastest rate in the cancer biomarkers market during 2024-2034. Many potential biomarkers have been quickly found in recent years thanks to the application of high-throughput omics technology. High throughput methods known as omics technologies enable the collection of vast quantities of information on a particular class of molecules in a single experiment. Healthcare is getting closer to the reality of precision medicine thanks to the advancements in technology that support these omics technologies.
North America dominated the cancer biomarkers market due to the presence of an advanced healthcare infrastructure, where the growth in cancer cases increased the demand for cancer biomarkers, driving the early adoption of new cancer detection tools and personalized treatments. The growth in R&D investments and precision medicine development also contributed to the market growth.
Over the course of the forecast period, factors, including the increasing incidence of cancer and the actions of major market players, are anticipated to propel market growth. The U.S. has seen a sharp rise in the number of cancer sufferers. Breast cancer may strike both men and women. However, breast cancer is quite uncommon in men and typically occurs in women. In March 2022, there will likely be 51,400 new cases of non-invasive (in situ) breast cancer and 287,850 new cases of invasive breast cancer found in women in the United States, according to Breastcancer.org. It is anticipated that the growing number of cancer cases will improve the utilization of cancer biomarkers for diagnosis, propelling the market for cancer biomarkers in North America.
For instance,
Throughout its long history, the Canadian Cancer Society has contributed to advancements in cancer prevention, diagnosis, treatment, and living with and beyond the disease. The group spent $44.7 million on cancer research and innovation initiatives in 2023.
The Asia Pacific area has become the most advantageous regional cancer biomarkers market firm worldwide due to the increasing incidence of various cancer kinds. Due to the increased desire for improved cancer diagnosis and therapies, this area has seen significant expenditures in oncology research, which has increased demand for cancer biomarkers. For cancer biomarker suppliers operating in this area, India, China, and Japan are expected to be the top three markets. In addition, it is anticipated that this area will eventually draw a large number of cancer biomarker firms due to its easier regulatory clearances than North America and Europe.
Affordable cancer treatments will be the main focus of the five-year India-UK Cancer Research Initiative, a cooperative bilateral research project between Cancer Research UK (CRUK) and the Department of Biotechnology, Ministry of Science & Technology, India. For this five-year project, CRUK and DBT will each provide £5 million, and they will look for additional money from other possible partners. The Department of Biotechnology (DBT) in India and Cancer Research UK are planning to start a £10 million bilateral research project that would concentrate on low-cost cancer treatment methods.
Europe is expected to grow at a notable rate in the foreseeable future. The rising prevalence of cancer and the growing research and development activities are the major growth factors of the market in Europe. Several government organizations encourage screening and early diagnosis of cancer, especially in high-risk individuals, promoting the need for cancer biomarkers. The EU “Beating Cancer Plan” aims for 90% of people who qualify to get screened for breast, cervical, and colorectal cancer by 2025. The growing demand for personalized medicines due to rapidly changing demographics augments market growth.
It is estimated that over 1.6 million people are living with cancer in Germany. Cancer poses a significant economic burden on the healthcare ecosystem. OECD estimated that the burden of cancer as a share of health expenditure is expected to rise at a rate of 9.1% between 2023 and 2050. Thus, government bodies create awareness for screening and early diagnosis of cancer, enabling healthcare professionals to provide early intervention.
South America is expected to grow significantly in the cancer biomarkers market during the forecast period, due to growing health awareness through the increasing government cancer screening program, which is increasing the adoption of cancer biomarkers. Growing cancer cases, R&D activities, and healthcare investments are also increasing their demand, enhancing the market growth.
Brazil Cancer Biomarkers Market Trends
A rise in the cancer burden across Brazil is increasing the demand for their early detection and personalized treatment option which is driving the adoption of cancer biomarkers. Moreover, growing health awareness and expanding healthcare infrastructure are also increasing their adoption rates to offer advanced diagnostic and treatment options.
MEA is expected to show lucrative growth in the cancer biomarkers market during the forecast period, due to the growing cancer burden, which is increasing the demand for cancer biomarkers for their early detection and the development of personalized treatment options. Increasing government initiatives, expanding healthcare, and growing demand for targeted therapies are also promoting the market growth.
Saudi Arabia Cancer Biomarkers Market Trends
The growing government initiatives in Saudi Arabia are increasing the use of cancer biomarkers to develop more accurate diagnostic solutions. Increasing cancer cases are also increasing the adoption of cancer biomarkers for the development of personalized medicines, genomic profiling, and liquid biopsies.
The growing cancer burden globally is increasing the demand for more accurate diagnostic tools and effective treatment options, which is increasing the use of their biomarkers, propelling the R&D activities.
The growing health awareness is increasing the demand for precision medicine, which is increasing the use of cancer biomarkers for the development of new targeted therapies and immunotherapies with improved patient outcomes.
Growth in patient awareness is increasing the demand for non-invasive testing, driving the development of liquid biopsies and other minimally invasive assays, which is increasing the demand for cancer biomarkers.
The growing technological advancements are accelerating the development of new genomic, proteomic profiling, and next-generation sequencing (NGS), and liquid biopsies, which are increasing the use of cancer biomarkers for the early and accurate detection of cancer.
In November 2024, to transform cancer research and care through ethical AI, the Cancer AI Alliance brings together leading cancer centers and AI experts. CAIA is coordinated by the Fred Hutch Cancer Center with assistance from AWS, Deloitte, Microsoft, and NVIDIA, totaling more than $40 million.
Researchers develop novel biomarkers that are involved in disease progression, such as circulating tumor DNA for non-invasive detection and monitoring.
Key Players: Biomark Diagnostics, Sino Biological, and Merck KgaA.
Clinical trials are conducted due to the increased use of precision medicine targeting biomarkers and specific oncogenic mutations.
Key Players: Diagnostica Stago R&D, Endomagentics Ltd., and Thermo Fisher Scientific.
Patient support & services refers to helping patients understand their test results and manage their personalized treatment plans. Patient support also indicate to providing reimbursement for cancer diagnosis and treatment.
By Type
By Biomolecule
By Application
By Technology
By Region
February 2026
February 2026
January 2026
December 2025
sales@towardshealthcare.com
+1 804-441-9344
